AIM
MCRB icon

Acrospire Investment Management’s Seres Therapeutics MCRB Stock Holding History

Acrospire Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-224
Closed -$50K – 2384
2017
Q1 		$50K Sell
224
-165
-42% -$33.5K 0.04% 958
2016
Q4 		$77K Buy
389
+304
+358% +$66.3K 0.03% 1102
2016
Q3 		$21K Buy
85
+50
+143% +$17.5K 0.01% 1491
2016
Q2 		$20K Buy
35
+5
+17% +$2.93K 0.01% 1521
2016
Q1 		$16K Buy
+30
New +$15.7K 0.01% 1609

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acrospire Investment Management's MCRB Position: Q2 2017 in Review

Acrospire Investment Management sold out of Seres Therapeutics (MCRB) in Q2 2017, closing a stake of 224 shares — an estimated $50K sold.

Acrospire Investment Management first reported a position in MCRB in Q1 2016 and held it in 5 quarters. The position peaked at $77K in Q4 2016. 74 funds tracked by Wall St. Rank hold MCRB as of Q2 2017.

  • Acrospire Investment Management reported no remaining Seres Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 224 Seres Therapeutics shares in Q2 2017, an estimated $50K.
  • Acrospire Investment Management first reported a position in Seres Therapeutics in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Seres Therapeutics position peaked at $77K in Q4 2016.
  • 74 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.